27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Amicus Therapeutics (NASDAQ:FOLD) moved higher by 0.2% in pre-market trading after the company reported Q4 results.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Quarterly Results
Earnings per share rose 22.86% over the past year to ($0.27), which missed the estimate of ($0.23).
Revenue of $70,571,000 higher by 27.63% from the same period last year, which beat the estimate of $70,060,000.
Looking Ahead
Amicus Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Conference Call Details
Date: Mar 01, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/pikiqnf7
Price Action
52-week high: $25.39
Company's 52-week low was at $6.25
Price action over last quarter: down 39.91%
Company Overview
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Currently, the company is focused on treating Fabry Disease with its treatment Galafold and developing additional therapies for Fabry patients. Amicus has also received breakthrough therapy designation that allows it to deploy a therapy for Pompe Disease in late-stage patients.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.